| Previous Close | 33.88 |
| Open | 33.95 |
| Bid | 34.08 x 100 |
| Ask | 34.27 x 100 |
| Day's Range | 33.92 - 34.48 |
| 52 Week Range | 29.83 - 37.39 |
| Volume | 2,446 |
| Avg. Volume | 21,575,643 |
| Market Cap | 203.26B |
| Beta | 1.06 |
| PE Ratio (TTM) | 28.67 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.28 (3.78%) |
| Ex-Dividend Date | 2017-05-10 |
| 1y Target Est | N/A |
- Market Realist•15 minutes ago
Vertex on the Street: Analysts’ Recommendations in June 2017
Vertex (VRTX) has planned to submit a new drug application to the FDA in 3Q17 for a Tezacaftor-Ivacaftor combination treatment for cystic fibrosis.
- TheStreet.com•51 minutes ago
15 Great Dividend Stocks to Own Should the Surging Stock Market Plunge This Summer
Here are the names.
- Reuters•4 hours ago
Novartis breast cancer drug Kisqali wins European panel nod
A European Medicines Agency panel recommended on Friday approving Novartis's Kisqali drug, bolstering the Swiss drugmaker's bid to challenge rival Pfizer's Ibrance against tough-to-treat breast cancer. ...
